<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
57894-514-01
</NDCCode>
<PackageDescription>
1 VIAL, SINGLE-DOSE in 1 CARTON (57894-514-01) / 14 mL in 1 VIAL, SINGLE-DOSE
</PackageDescription>
<NDC11Code>
57894-0514-01
</NDC11Code>
<ProductNDC>
57894-514
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Rybrevant Faspro
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Amivantamab And Hyaluronidase-lpuj (human Recombinant)
</NonProprietaryName>
<DosageFormName>
INJECTION
</DosageFormName>
<RouteName>
SUBCUTANEOUS
</RouteName>
<StartMarketingDate>
20251217
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
BLA
</MarketingCategoryName>
<ApplicationNumber>
BLA761433
</ApplicationNumber>
<LabelerName>
Janssen Biotech, Inc.
</LabelerName>
<SubstanceName>
AMIVANTAMAB; HYALURONIDASE (HUMAN RECOMBINANT)
</SubstanceName>
<StrengthNumber>
2240; 28000
</StrengthNumber>
<StrengthUnit>
mg/14mL; mg/14mL
</StrengthUnit>
<Pharm_Classes>
Endoglycosidase [EPC], Glycoside Hydrolases [CS]
</Pharm_Classes>
<DEASchedule/>
<Status>
Active
</Status>
<LastUpdate>
2025-12-19
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20251217
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>